Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury

Journal of Pineal Research

Volumn 57, Issue 1, 2014, Pages 16-32

  Chen, Hong Hwa ^a   Lin, Kun Chen ^a   Wallace, Christopher G ^b   Chen, Yen Ta ^a   Yang, Chih Chao ^a   Leu, Steve ^a   Chen, Yi Ching ^a   Sun, Cheuk Kwan ^c   Tsai, Tzu Hsien ^a   Chen, Yung Lung ^a   Chung, Sheng Ying ^a   Chang, Chia Lo ^a   Yip, Hon Kan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c E DA HOSPITAL   (Taiwan)

Author keywords

acute kidney injury; adipose derived mesenchymal stem cells; inflammation; melatonin; oxidative stress; sepsis syndrome

Indexed keywords

CASPASE 3; CD14 ANTIGEN; GELATINASE B; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1; MELATONIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; RANTES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADIPOSE DERIVED MESENCHYMAL STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CECAL LIGATION AND PUNCTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; IMMUNOREACTIVITY; LIGATION; MESENCHYMAL STEM CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PUNCTURE; RAT; REGULATORY T LYMPHOCYTE; SEPSIS; ACUTE KIDNEY INJURY; ADIPOSE TISSUE; ANIMAL; COMPLICATION; CYTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; WESTERN BLOTTING;

ACUTE KIDNEY INJURY; ADIPOSE TISSUE; ANIMALS; BLOTTING, WESTERN; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; RATS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904514095     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12140     Document Type: Article

References (40)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
2. Cronshaw HL, Daniels R, Bleetman A, et al. Impact of the Surviving Sepsis Campaign on the recognition and management of severe sepsis in the emergency department: are we failing? Emerg Med J 2011; 28: 670-675.
3. Malacarne P, Langer M, Nascimben E, et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. Crit Care Med 2008; 36: 1105-1113.
4. Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004; 30: 580-588.
5. Le Gall JR, Alberti C, Brun Buisson C,. Epidemiology of infection and sepsis in intensive care unit patients. Bull Acad Natl Med 2004; 188: 1115-1125; discussion 1125-6.
6. Hietbrink F, Koenderman L, Althuizen M, et al. Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. Shock 2013; 40: 21-27.
7. Hein F, Massin F, Cravoisy-Popovic A, et al. The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care 2010; 14: R19.
8. Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009; 35: 678-686.
9. Hartemink KJ, Groeneveld AB,. The hemodynamics of human septic shock relate to circulating innate immunity factors. Immunol Invest 2010; 39: 849-862.
10. Monserrat J, de Pablo R, Reyes E, et al. Clinical relevance of the severe abnormalities of the T cell compartment in septic shock patients. Crit Care 2009; 13: R26.
11. Maury E, Blanchard HS, Chauvin P, et al. Circulating endotoxin and antiendotoxin antibodies during severe sepsis and septic shock. J Crit Care 2003; 18: 115-120.
12. Fry DE,. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012; 78: 1-8.
13. Taylor AL, ', Llewelyn MJ,. Superantigen-induced proliferation of human CD4+CD25- T cells is followed by a switch to a functional regulatory phenotype. J Immunol 2010; 185: 6591-6598.
14. Reiter RJ, Tan DX, Poeggeler B, et al. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 1994; 719: 1-12.
15. Mauriz JL, Collado PS, Veneroso C, et al. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
16. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
17. Sener G, Sehirli AO, Keyer-Uysal M, et al. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res 2002; 32: 120-126.
18. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
19. Kesik V, Guven A, Vurucu S, et al. Melatonin and 1400 W ameliorate both intestinal and remote organ injury following mesenteric ischemia/reperfusion. J Surg Res 2009; 157: e97-e105.
20. Patschan D, Hildebrandt A, Rinneburger J, et al. The hormone melatonin stimulates renoprotective effects of "early outgrowth" endothelial progenitor cells in acute ischemic kidney injury. Am J Physiol Renal Physiol 2012; 302: F1305-F1312.
21. Kilic U, Yilmaz B, Ugur M, et al. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. J Pineal Res 2012; 52: 228-235.
22. le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11-20.
23. Sun CK, Yen CH, Lin YC, et al. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med 2011; 9: 118.
24. Maumus M, Guerit D, Toupet K, et al. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther 2011; 2: 14.
25. Chen YT, Sun CK, Lin YC, et al. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2011; 9: 51.
26. Thum T, Bauersachs J, Poole-Wilson PA, et al. The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol 2005; 46: 1799-1802.
27. Yip HK, Chang YC, Wallace CG, et al. Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury. J Pineal Res 2013; 54: 207-221.
28. Chang CL, Leu S, Sung HC, et al. Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J Transl Med 2012; 10: 244.
29. Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009; 4: 31-36.
30. Zhu W, Chen J, Cong X, et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem cells 2006; 24: 416-425.
31. Alamili M, Bendtzen K, Lykkesfeldt J, et al. Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. J Crit Care 2014; 29: 184 e9-184 e13.
32. Galley HF, Lowes DA, Allen L, et al. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res 2014; 56: 427-438.
33. da Silva LB, Palma PV, Cury PM, et al. Evaluation of stem cell administration in a model of kidney ischemia-reperfusion injury. Int Immunopharmacol 2007; 7: 1609-1616.
34. Li B, Cohen A, Hudson TE, et al. Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation 2010; 121: 2211-2220.
35. Togel F, Weiss K, Yang Y, et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol 2007; 292: F1626-F1635.
36. Dekel B, Shezen E, Even-Tov-friedman S, et al. Transplantation of human hematopoietic stem cells into ischemic and growing kidneys suggests a role in vasculogenesis but not tubulogenesis. Stem Cells 2006; 24: 1185-1193.
37. Imberti B, Morigi M, Tomasoni S, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007; 18: 2921-2928.
38. Lange C, Togel F, Ittrich H, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005; 68: 1613-1617.
39. Bussolati B, Tetta C, Camussi G,. Contribution of stem cells to kidney repair. Am J Nephrol 2008; 28: 813-822.
40. Lowes DA, Webster NR, Murphy MP, et al. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth 2013; 110: 472-480.